The Trend of COVID-19 Vaccination Rate and Its associated factors: a multicenter household survey (Preprint)

Author:

Wu Jian,Li Quanman,Tarimo Clifford Silver,Wang Meiyun,Miao Yudong

Abstract

BACKGROUND

Vaccination against COVID-19 has saved tens of thousands of lives worldwide since its introduction. However, with time elapsing, improving the vaccination coverage in China may be confronted with a number of obstacles.

OBJECTIVE

In this nationwide study, we aimed to evaluate the COVID-19 vaccination rate and its potential influencing factors in the Chinese population.

METHODS

We collected data from the national multicenter household survey in China using a stratified random sampling method from 3 Aug. 2022 to 14 Aug. 2022. We recruited respondents aged 18 years or older in the selected households. We investigated the variation in the COVID-19 vaccination rate for the first dose, full dose as well as the booster vaccine, and identified the associated factors for vaccination using multiple logistic regression models.

RESULTS

A total of 6781 participants (2556 households) were included in this study. Up to 14 Aug. 2022, 6613 participants (97.52%, 95%CI: 97.15%-97.89%) received the first dose of COVID-19 vaccines; 6319 participants (93.19%, 95%CI: 92.59%-93.79%) received the full-dose vaccines while 5435 participants (80.15%, 95%CI: 79.20%-81.10%) received the COVID-19 booster vaccines. Participant’s age, chronic disease status and self-efficiency were found to be significant influencing factors for receiving first dose vaccine, full dose vaccine and booster dose vaccine for COVID-19. Ineligibility for vaccination was the primary reason that participants did not receive the booster vaccine (74.98%). This is followed by vaccination safety concerns, which make up 8% of all the highlighted reasons.

CONCLUSIONS

China has surpassed initial targets of WHO's Global COVID-19 Vaccination Strategy. To increase vaccine coverage, policymakers should develop more specialized measures for special groups, including young adults, people with chronic disease, and those with low self-efficacy.

CLINICALTRIAL

Not applicable.

Publisher

JMIR Publications Inc.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3